Elevance Health Inc.

This post analyzes ELV's Q1 2026 beat, with adjusted diluted EPS of 12.58 versus consensus 10.82, and the subsequent raise in full‑year 2026 adjusted EPS guidance to at least 26.75 alongside an operating cash flow outlook of at least 5.5 billion. It argues the stock is undervalued relative to TIKR's mid‑case target of 534 by December 2030, highlighting margin recovery prospects in Medicaid and CarelonRx while flagging risks around medical cost trends and Q2 claims development.

This PDF provides a hybrid technical and fundamental analyst report dated 2026‑04‑24, assigning a Hold rating with roughly 10.8% upside to a consensus target price of 382.19 and documenting a backtested win rate of 44.4% with 15.1% total return on ELV trades. It notes a neutral fundamental outlook given modest 2.6% revenue growth and −16.8% earnings growth, strong institutional ownership of 95.6%, and overbought technical indicators, while emphasizing volatility, regulatory risk, and medical cost pressures.

This article frames ELV's 2025 drawdown and CMS sanctions as a potential cyclical trough, weighing a 2027 recovery thesis built on at least 12% adjusted EPS growth, 2.3 billion planned 2026 buybacks, and Carelon's expanding external revenue pipeline against the risk that sanctions and Medicaid margins remain structurally impaired. It stresses that Wall Street's mean price target of about 380.95 implies roughly 26.7% upside from the 300.74 share price at publication, yet cautions that prolonged sanctions or weaker rate‑to‑trend alignment could break the margin recovery narrative.

This valuation note reviews ELV's 2025 results and 2026 guidance, highlighting revenue growth to 199.1 billion, a slight dip in net income from 6.0 to 5.7 billion, and management's projection of at least 22.30 EPS in 2026 alongside a minor expected decline in operating revenue. It concludes the shares were about 13.2% undervalued versus a fair value estimate of 390.54 at a closing price of 338.98, positioning ELV as an attractive opportunity if investors are comfortable with Medicaid declines, cost pressures, and regulatory uncertainties.

This piece analyzes Elevance's exit from standalone Part D and selected Medicare Advantage markets as a margin‑protective retrenchment, noting the cut in 2025 adjusted EPS guidance to about 30 from a prior 34.15–34.85 range and an expected roughly 375 million hit from losing a legal battle over 2025 star ratings. Despite calling out a low forward P/E of about 10.06 and a Value Score of A, it emphasizes earnings headwinds and assigns ELV a Zacks Rank #4 (Sell), implying a cautious to negative stance on the stock's near‑term performance.

This news‑style analysis discusses Elevance's earnings resilience and revenue of roughly 177 billion, pointing to multi‑year revenue growth and a P/E around 13.13 as evidence of reasonable valuation and solid financial footing despite Medicaid‑related EPS pressure. It combines fundamental and technical commentary, advising a long position around 300 with resistance near 435 and highlighting board changes, digital asthma initiatives, and anticipated EPS recovery by 2026 as upside catalysts subject to policy and Medicaid‑environment risks.

This extensive open‑access report presents a structured bull‑versus‑bear investment thesis, arguing that the market may be overreacting to elevated medical cost trends and Medicaid/ACA margin compression while underappreciating Elevance's integrated Carelon platform, cash generation, and disciplined capital allocation. It details industry headwinds, segment‑level performance, growth opportunities in Medicare Advantage and Carelon, and a robust risk section on reimbursement, regulatory, and medical cost uncertainty, ultimately framing ELV as a high‑quality franchise with a debated but potentially compelling long‑term risk‑reward profile.